Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

por Sangro, Bruno, Yau, Thomas, El‐Khoueiry, Anthony B., Kudo, Masatoshi, Shen, Yun, Tschaika, Marina, Roy, Amit, Feng, Yan, Gao, Ling, Aras, Urvi
Publicado 2023

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

por Hack, Stephen P., Verret, Wendy, Mulla, Sohail, Liu, Bo, Wang, Yulei, Macarulla, Teresa, Ren, Zhenggang, El-Khoueiry, Anthony B., Zhu, Andrew X.
Publicado 2021

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the...

por El-Khoueiry, Anthony B., Meyer, Tim, Cheng, Ann-Lii, Rimassa, Lorenza, Sen, Suvajit, Milwee, Steven, Kelley, Robin Kate, Abou-Alfa, Ghassan K.
Publicado 2022

Presentation, Management, and Outcomes Across the Rural-Urban Continuum for Hepatocellular Carcinoma

por Zhou, Kali, Pickering, Trevor A, Gainey, Christina S, Cockburn, Myles, Stern, Mariana C, Liu, Lihua, Unger, Jennifer B, El-Khoueiry, Anthony B, Terrault, Norah A
Publicado 2020

Monitoring Twitter Conversations for Targeted Recruitment in Cancer Trials in Los Angeles County: Protocol for a Mixed-Methods Pilot Study

por Reuter, Katja, Angyan, Praveen, Le, NamQuyen, MacLennan, Alicia, Cole, Sarah, Bluthenthal, Ricky N, Lane, Christianne J, El-Khoueiry, Anthony B, Buchanan, Thomas A
Publicado 2018

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

por El-Khoueiry, Anthony B., Clarke, James, Neff, Tobias, Crossman, Tim, Ratia, Nirav, Rathi, Chetan, Noto, Paul, Tarkar, Aarti, Garrido-Laguna, Ignacio, Calvo, Emiliano, Rodón, Jordi, Tran, Ben, O’Dwyer, Peter J., Cuker, Adam, Abdul Razak, Albiruni R.
Publicado 2023

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

por Kelley, Robin Kate, Miksad, Rebecca, Cicin, Irfan, Chen, YenHsun, Klümpen, Heinz-Josef, Kim, Stefano, Lin, Zhong-Zhe, Youkstetter, Jillian, Hazra, Saswati, Sen, Suvajit, Cheng, Ann-Lii, El-Khoueiry, Anthony B., Meyer, Tim, Abou-Alfa, Ghassan K.
Publicado 2021

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

por Diab, Adi, Hamid, Omid, Thompson, John A., Ros, Willeke, Eskens, Ferry A.L.M., Doi, Toshihiko, Hu-Lieskovan, Siwen, Klempner, Samuel J., Ganguly, Bishu, Fleener, Catherine, Wang, Xiao, Joh, Tenshang, Liao, Ken, Salek-Ardakani, Shahram, Taylor, Carrie Turich, Chou, Jeffrey, El-Khoueiry, Anthony B.
Publicado 2022

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

por Yau, Thomas, Zagonel, Vittorina, Santoro, Armando, Acosta-Rivera, Mirelis, Choo, Su Pin, Matilla, Ana, He, Aiwu Ruth, Cubillo Gracian, Antonio, El-Khoueiry, Anthony B., Sangro, Bruno, Eldawy, Tarek E., Bruix, Jordi, Frassineti, Giovanni Luca, Vaccaro, Gina M., Tschaika, Marina, Scheffold, Christian, Koopmans, Petra, Neely, Jaclyn, Piscaglia, Fabio
Publicado 2023

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

por Hamid, Omid, Chiappori, Alberto A, Thompson, John A, Doi, Toshihiko, Hu-Lieskovan, Siwen, Eskens, Ferry A L M, Ros, Willeke, Diab, Adi, Spano, Jean-Philippe, Rizvi, Naiyer A, Wasser, Jeffrey S, Angevin, Eric, Ott, Patrick A, Forgie, Alison, Yang, Wenjing, Guo, Cen, Chou, Jeffrey, El-Khoueiry, Anthony B
Publicado 2022

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

por Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L, Lim, Ho Yeong, Baron, Ari D, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C, Milwee, Steven, El-Khoueiry, Anthony B, Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K
Publicado 2020

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

por Yau, Thomas, Kang, Yoon-Koo, Kim, Tae-You, El-Khoueiry, Anthony B., Santoro, Armando, Sangro, Bruno, Melero, Ignacio, Kudo, Masatoshi, Hou, Ming-Mo, Matilla, Ana, Tovoli, Francesco, Knox, Jennifer J., Ruth He, Aiwu, El-Rayes, Bassel F., Acosta-Rivera, Mirelis, Lim, Ho-Yeong, Neely, Jaclyn, Shen, Yun, Wisniewski, Tami, Anderson, Jeffrey, Hsu, Chiun
Publicado 2020

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

por Greten, Tim F, Abou-Alfa, Ghassan K, Cheng, Ann-Lii, Duffy, Austin G, El-Khoueiry, Anthony B., Finn, Richard S, Galle, Peter R, Goyal, Lipika, He, Aiwu Ruth, Kaseb, Ahmed O, Kelley, Robin Kate, Lencioni, Riccardo, Lujambio, Amaia, Mabry Hrones, Donna, Pinato, David J, Sangro, Bruno, Troisi, Roberto I, Wilson Woods, Andrea, Yau, Thomas, Zhu, Andrew X, Melero, Ignacio
Publicado 2021

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

por Zhu, Andrew X., Macarulla, Teresa, Javle, Milind M., Kelley, R. Kate, Lubner, Sam J., Adeva, Jorge, Cleary, James M., Catenacci, Daniel V. T., Borad, Mitesh J., Bridgewater, John A., Harris, William P., Murphy, Adrian G., Oh, Do-Youn, Whisenant, Jonathan R., Lowery, Maeve A., Goyal, Lipika, Shroff, Rachna T., El-Khoueiry, Anthony B., Chamberlain, Christina X., Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Liu, Hua, Gliser, Camelia, Pandya, Shuchi S., Valle, Juan W., Abou-Alfa, Ghassan K.
Publicado 2021